SecBot SecBot

IMRN

Immuron Ltd
Nasdaq· Pharmaceutical Preparations· Inc. C3· CIK 0001660046 Biotech & Drug Discovery
$0.9200 −0.03 (−3.56%)
Oct 26 4:00 PM ET · prev $0.9540
Market cap
$7.7M
Nano cap
Median target
🔒 Subscribers only
1 year
−58.2%
from $2.20 · Oct 27
30 days
−20.7%
from $1.16
52-week range
$0.7000–2.20
−58% from high · low Mar 23
Avg volume 20D
47.9K
Oct 13 spike 196.6K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
23
analyzed by SecBot
SecBot read MIXED 14 reports · 90 days
Balance 0 bearish · 0 bullish · 1 mixed · 13 neutral oldest → newest, height = score
Avg score ·High conf. 11/14
Strongest MIXED Immuron Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2026. Revenue increased…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 1 added (0 new), 1 trimmed or exited.

  • TrendDOWNTREND

    22% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
CITADEL ADVISORS LLCDOUBLED43,123$45.7K
MORGAN STANLEYNEAR_EXIT1,700$1.8K
MORGAN STANLEYTRIM30,574$23.7K
RHUMBLINE ADVISERSADD7,367$5.7K
MORGAN STANLEYDOUBLED57,381$43.8K
BNP PARIBAS FINANCIAL MARKETSDOUBLED4,700$3.6K
UBS Group AGDOUBLED4,143$3.2K
MORGAN STANLEYDOUBLED18,253$34.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

last action Sep 2024

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Sep 26, 2024Litchfield Hills
INITIATE
INITIATEBuy
Oct 18, 2017HC Wainwright & Co.
INITIATE
INITIATEBuy

Earnings setup

Estimates
PeriodEPS est.Range30D rev.Revenue
Current Q———$0.00
Next Q———$0.00
Current FY-$0.02-$0.02–-$0.02-25.8%$9.0M
Next FY———$0.00
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Oct 27, 2026
Press release
🔒 Fresh data, subscribers only
Oct 22, 2026
Press release
Immuron CEO, Steven Lydeamore presentation at Emerging Growth Conference
MELBOURNE, Australia, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to advise our Chief Executive Officer…
Sep 28, 2026
Reg SHO list
Reg SHO Threshold: IMRN exited the threshold list
IMMURON LTD SPONSORED ADR (AUS | On list since 2026-09-14
Sep 14, 2026
Reg SHO list
Reg SHO Threshold: IMRN entered the threshold list
IMMURON LTD SPONSORED ADR (AUS | 5+ consecutive settlement days of fails-to-deliver ≥10k shares and ≥0.5% of shares outstanding
Sep 4, 2026
Contract
Immuron to launch PROIBS® in the United States
MELBOURNE, Australia, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) is pleased to announce that it has executed an…

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 27, 2026 Other
🔒 Fresh data, subscribers only
Oct 23, 2026 SEC
Immuron Ltd filed a Form 6-K to reduce the remaining capacity under its existing at-the-market (ATM) offering…
6-K — Impact 3/10
Oct 23, 2026 SEC
Immuron Ltd filed a 424B5 prospectus supplement to reduce the maximum offering amount under its existing at-the-market…
424B5 — Impact 3/10
Sep 4, 2026 Press
Immuron announced an exclusive U.S. distribution agreement with Calmino group AB for PROIBS®, a medical device for…
Impact 4/10
Aug 28, 2026 Press
Immuron reported FY26 results with record sales of A$7.7M (+6% YoY) and net profit improvement of A$1.4M. The company…
Impact 4/10
Jun 30, 2026 Inst.
CITADEL ADVISORS LLC — DOUBLED
43,123 shares ($45.7K)
Jun 30, 2026 Inst.
MORGAN STANLEY — NEAR_EXIT
1,700 shares ($1.8K)

SecBot reports

23 filings · 3 press releases · 3 bullish · 0 bearish · 1 mixed · 19 neutral
All IMRN filing & press-release reports (26)